The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we treat metabolic disorders. These groundbreaking therapies belong to a class known as GLP-1 receptor agonists, which duplicate the effects of a natural hormone that manages sugar levels and food intake. Originally, developed for diabetic conditions, the